# Oshkosh Corp: financial statements, quarterly

OSK · NYSE · CIK 775158 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/osk.md) · [Financials](/companies/osk/financials.md) · [Filings](/companies/osk/filings.md) · [Insiders](/companies/osk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/osk/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,413](/filings/0000950170-24-088482.md) | [2,510](/filings/0000950170-24-118922.md) | [2,467 d](/filings/0001193125-26-054061.md) | [2,544](/filings/0000950170-25-060988.md) | [2,847](/filings/0000950170-25-101362.md) | [2,741](/filings/0001193125-25-256137.md) | [2,598 d](/filings/0001193125-26-054061.md) | [2,313](/filings/0001193125-26-214298.md) | [2,732](/filings/0000950170-25-101362.md) | [2,689](/filings/0001193125-25-256137.md) | [2,689 d](/filings/0001193125-26-054061.md) | [2,318](/filings/0001193125-26-214298.md) |
| Cost of revenue | $m | [1,989](/filings/0000950170-24-088482.md) | [2,042](/filings/0000950170-24-118922.md) | [2,012 d](/filings/0001193125-26-054061.md) | [2,074](/filings/0000950170-25-060988.md) | [2,301](/filings/0000950170-25-101362.md) | [2,235](/filings/0001193125-25-256137.md) | [2,151 d](/filings/0001193125-26-054061.md) | [1,913](/filings/0001193125-26-214298.md) | [2,208](/filings/0000950170-25-101362.md) | [2,218](/filings/0001193125-25-256137.md) | [2,265 d](/filings/0001193125-26-054061.md) | [2,006](/filings/0001193125-26-214298.md) |
| Gross profit | $m | [425](/filings/0000950170-24-088482.md) | [468](/filings/0000950170-24-118922.md) | [454 d](/filings/0001193125-26-054061.md) | [470](/filings/0000950170-25-060988.md) | [546](/filings/0000950170-25-101362.md) | [506](/filings/0001193125-25-256137.md) | [447 d](/filings/0001193125-26-054061.md) | [400](/filings/0001193125-26-214298.md) | [525](/filings/0000950170-25-101362.md) | [471](/filings/0001193125-25-256137.md) | [424 d](/filings/0001193125-26-054061.md) | [312](/filings/0001193125-26-214298.md) |
| Research and development | $m | not reported | not reported | not reported | [39.3](/filings/0000950170-25-060988.md) | [44.1](/filings/0000950170-25-101362.md) | [40.2](/filings/0001193125-25-256137.md) | [45.5 d](/filings/0001193125-26-054061.md) | [48.8](/filings/0001193125-26-214298.md) | [45.0](/filings/0000950170-25-101362.md) | [39.4](/filings/0001193125-25-256137.md) | [40.5 d](/filings/0001193125-26-054061.md) | [39.1](/filings/0001193125-26-214298.md) |
| Selling, general and administrative | $m | [185](/filings/0000950170-24-088482.md) | [202](/filings/0000950170-24-118922.md) | [224 d](/filings/0001193125-26-054061.md) | [197](/filings/0000950170-25-060988.md) | [220](/filings/0000950170-25-101362.md) | [226](/filings/0001193125-25-256137.md) | [209 d](/filings/0001193125-26-054061.md) | [211](/filings/0001193125-26-214298.md) | [213](/filings/0000950170-25-101362.md) | [196](/filings/0001193125-25-256137.md) | [198 d](/filings/0001193125-26-054061.md) | [216](/filings/0001193125-26-214298.md) |
| Operating income | $m | [235](/filings/0000950170-24-088482.md) | [257](/filings/0000950170-24-118922.md) | [215 d](/filings/0001193125-26-054061.md) | [260](/filings/0000950170-25-060988.md) | [261](/filings/0000950170-25-101362.md) | [266](/filings/0001193125-25-256137.md) | [224 d](/filings/0001193125-26-054061.md) | [175](/filings/0001193125-26-214298.md) | [292](/filings/0000950170-25-101362.md) | [260](/filings/0001193125-25-256137.md) | [212 d](/filings/0001193125-26-054061.md) | [82.0](/filings/0001193125-26-214298.md) |
| Income tax | $m | [56.3](/filings/0000950170-24-088482.md) | [55.3](/filings/0000950170-24-118922.md) | [44.2 d](/filings/0001193125-26-054061.md) | [54.7](/filings/0000950170-25-060988.md) | [53.5](/filings/0000950170-25-101362.md) | [56.6](/filings/0001193125-25-256137.md) | [45.2 d](/filings/0001193125-26-054061.md) | [36.8](/filings/0001193125-26-214298.md) | [65.2](/filings/0000950170-25-101362.md) | [41.7](/filings/0001193125-25-256137.md) | [47.8 d](/filings/0001193125-26-054061.md) | [10.5](/filings/0001193125-26-214298.md) |
| Net income | $m | [175](/filings/0000950170-24-088482.md) | [184](/filings/0000950170-24-118922.md) | [151 d](/filings/0001193125-26-054061.md) | [179](/filings/0000950170-25-060988.md) | [169](/filings/0000950170-25-101362.md) | [180](/filings/0001193125-25-256137.md) | [153 d](/filings/0001193125-26-054061.md) | [112](/filings/0001193125-26-214298.md) | [205](/filings/0000950170-25-101362.md) | [196](/filings/0001193125-25-256137.md) | [134 d](/filings/0001193125-26-054061.md) | [43.1](/filings/0001193125-26-214298.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss
- Diluted EPS: not reported
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.4](/filings/0000950170-23-036332.md) | [0.1](/filings/0000950170-23-055497.md) | [0.1](/filings/0000950170-25-024305.md) | [0.1](/filings/0000950170-24-048137.md) | [0.1](/filings/0000950170-24-088482.md) | [0.2](/filings/0000950170-24-118922.md) | [0.2](/filings/0001193125-26-054061.md) | [0.2](/filings/0000950170-25-060988.md) | [0.2](/filings/0000950170-25-101362.md) | [0.2](/filings/0001193125-25-256137.md) | [0.5](/filings/0001193125-26-214298.md) | [0.3](/filings/0001193125-26-214298.md) |
| Current assets | $bn | [4.4](/filings/0000950170-23-036332.md) | [4.5](/filings/0000950170-23-055497.md) | [4.5](/filings/0000950170-25-024305.md) | [4.7](/filings/0000950170-24-048137.md) | [5.0](/filings/0000950170-24-088482.md) | [5.1](/filings/0000950170-24-118922.md) | [4.5](/filings/0001193125-26-054061.md) | [4.9](/filings/0000950170-25-060988.md) | [5.0](/filings/0000950170-25-101362.md) | [4.9](/filings/0001193125-25-256137.md) | [5.2](/filings/0001193125-26-214298.md) | [5.1](/filings/0001193125-26-214298.md) |
| Total assets | $bn | [8.0](/filings/0000950170-23-036332.md) | [8.9](/filings/0000950170-23-055497.md) | [9.1](/filings/0000950170-25-024305.md) | [9.5](/filings/0000950170-24-048137.md) | [9.7](/filings/0000950170-24-088482.md) | [9.9](/filings/0000950170-24-118922.md) | [9.4](/filings/0001193125-26-054061.md) | [9.8](/filings/0000950170-25-060988.md) | [10.0](/filings/0000950170-25-101362.md) | [9.8](/filings/0001193125-25-256137.md) | [10.1](/filings/0001193125-26-214298.md) | [10.0](/filings/0001193125-26-214298.md) |
| Current liabilities | $bn | [2.4](/filings/0000950170-23-036332.md) | [3.1](/filings/0000950170-23-055497.md) | [3.1](/filings/0000950170-25-024305.md) | [3.3](/filings/0000950170-24-048137.md) | [3.5](/filings/0000950170-24-088482.md) | [3.5](/filings/0000950170-24-118922.md) | [3.0](/filings/0001193125-26-054061.md) | [2.7](/filings/0000950170-25-060988.md) | [2.7](/filings/0000950170-25-101362.md) | [2.5](/filings/0001193125-25-256137.md) | [2.7](/filings/0001193125-26-214298.md) | [3.1](/filings/0001193125-26-214298.md) |
| Long-term debt | $bn | [0.6](/filings/0000950170-23-036332.md) | [0.6](/filings/0000950170-23-055497.md) | [0.6](/filings/0000950170-25-024305.md) | [0.6](/filings/0000950170-24-048137.md) | [0.6](/filings/0000950170-24-088482.md) | [0.6](/filings/0000950170-24-118922.md) | [0.6](/filings/0001193125-26-054061.md) | [1.1](/filings/0000950170-25-060988.md) | [1.1](/filings/0000950170-25-101362.md) | [1.1](/filings/0001193125-25-256137.md) | [1.1](/filings/0001193125-26-214298.md) | [0.6](/filings/0001193125-26-214298.md) |
| Current portion of debt | $bn | not reported | [0.5](/filings/0000950170-23-055497.md) | [0.2](/filings/0000950170-25-024305.md) | [0.6](/filings/0000950170-24-048137.md) | [1.0](/filings/0000950170-24-088482.md) | [0.9](/filings/0000950170-24-118922.md) | [0.4](/filings/0001193125-26-054061.md) | [0.4](/filings/0000950170-25-060988.md) | [0.4](/filings/0000950170-25-101362.md) | [0.1](/filings/0001193125-25-256137.md) | [0.0](/filings/0001193125-26-214298.md) | [0.5](/filings/0001193125-26-214298.md) |
| Shareholders' equity | $bn | [3.4](/filings/0000950170-23-036332.md) | [3.5](/filings/0000950170-23-055497.md) | [3.7](/filings/0000950170-25-024305.md) | [3.8](/filings/0000950170-24-048137.md) | [3.9](/filings/0000950170-24-088482.md) | [4.1](/filings/0000950170-24-118922.md) | [4.2](/filings/0001193125-26-054061.md) | [4.2](/filings/0000950170-25-060988.md) | [4.5](/filings/0000950170-25-101362.md) | [4.5](/filings/0001193125-25-256137.md) | [4.5](/filings/0001193125-26-214298.md) | [4.5](/filings/0001193125-26-214298.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(126) d](/filings/0000950170-24-088482.md) | [167 d](/filings/0000950170-24-118922.md) | [480 d](/filings/0001193125-26-054061.md) | [(356)](/filings/0000950170-25-060988.md) | [(211) d](/filings/0000950170-25-101362.md) | [326 d](/filings/0001193125-25-256137.md) | [791 d](/filings/0001193125-26-054061.md) | [(395)](/filings/0001193125-26-214298.md) | [89.2 d](/filings/0000950170-25-101362.md) | [489 d](/filings/0001193125-25-256137.md) | [600 d](/filings/0001193125-26-054061.md) | [(161)](/filings/0001193125-26-214298.md) |
| Capital expenditure | $m | [18.3 d](/filings/0000950170-24-088482.md) | [98.2 d](/filings/0000950170-24-118922.md) | [97.3 d](/filings/0001193125-26-054061.md) | [100](/filings/0000950170-25-060988.md) | [41.5](/filings/0000950170-25-101362.md) | [55.2](/filings/0001193125-25-256137.md) | [87.5 d](/filings/0001193125-26-054061.md) | [40.3](/filings/0001193125-26-214298.md) | [54.3](/filings/0000950170-25-101362.md) | [38.9](/filings/0001193125-25-256137.md) | [59.8 d](/filings/0001193125-26-054061.md) | [28.1](/filings/0001193125-26-214298.md) |
| Dividends paid | $m | [26.8 d](/filings/0000950170-24-088482.md) | [26.7 d](/filings/0000950170-24-118922.md) | [26.9 d](/filings/0001193125-26-054061.md) | [30.1](/filings/0000950170-25-060988.md) | [30.1 d](/filings/0000950170-25-101362.md) | [29.9 d](/filings/0001193125-25-256137.md) | [29.9 d](/filings/0001193125-26-054061.md) | [32.9](/filings/0001193125-26-214298.md) | [32.8 d](/filings/0000950170-25-101362.md) | [32.6 d](/filings/0001193125-25-256137.md) | [32.1 d](/filings/0001193125-26-054061.md) | [35.6](/filings/0001193125-26-214298.md) |
| Share repurchases | $m | [7.4 d](/filings/0000950170-24-088482.md) | [0.0 d](/filings/0000950170-24-118922.md) | [(0.1) d](/filings/0001193125-26-054061.md) | [15.1](/filings/0000950170-25-060988.md) | [39.5 d](/filings/0000950170-25-101362.md) | [11.0 d](/filings/0001193125-25-256137.md) | [50.4 d](/filings/0001193125-26-054061.md) | [28.7](/filings/0001193125-26-214298.md) | [40.0 d](/filings/0000950170-25-101362.md) | [90.6 d](/filings/0001193125-25-256137.md) | [119 d](/filings/0001193125-26-054061.md) | [47.3](/filings/0001193125-26-214298.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [66.0](/filings/0000950170-23-036332.md) | [65.8](/filings/0000950170-23-055497.md) | [65.8](/filings/0000950170-24-048137.md) | [65.7](/filings/0000950170-24-088482.md) | [65.9](/filings/0000950170-24-118922.md) | [66.1](/filings/0000950170-25-060988.md) | [65.9](/filings/0000950170-25-101362.md) | [65.7](/filings/0001193125-25-256137.md) | [65.1](/filings/0001193125-26-214298.md) | [64.8](/filings/0000950170-25-101362.md) | [64.6](/filings/0001193125-25-256137.md) | [63.3](/filings/0001193125-26-214298.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 62,351,309 at 2026-05-01, from the cover of the [10-Q filed 2026-05-08](/filings/0001193125-26-214298.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.